Nanovaccine‐Mediated Cell Selective Delivery of Neoantigens Potentiating Adoptive Dendritic Cell Transfer for Personalized Immunization

Authors:

Abstract
Neoantigen vaccines and adoptive dendritic cell (DC) transfer are major clinical approaches to initiate personalized immunity in cancer patients. However, the immunization efficacy is largely limited by the in vivo trajectory including neoantigens’ access to resident DCs and DCs’ access to lymph nodes (LNs). Herein, an innovative strategy is proposed to improve personalized immunization through neoantigen‐loaded nanovaccines synergized with adoptive DC transfer. It is found that it enables selective delivery of neoantigens to resident DCs and macrophages by coating cancer cell membranes onto neoantigen‐loaded nanoparticles. In addition, the nanovaccines promote the secretion of chemokine C‐C motif ligand 2 (CCL2), CCL3, and C‐X‐C motif ligand 10 from macrophages, thus potentiating the access of transferred DCs to LNs. This immunization strategy enables coordinated delivery of identified neoantigens and autologous tumor lysate‐derived undefined antigens, leading to initiation of antitumor T cell immunity in a personalized manner. It significantly inhibits tumor growth in prophylactic and established mouse tumor models. The findings provide a new vision for potentiating adoptive cell transfer by nanovaccines, which may open the door to a transformative possibility for improving personalized immunization.
Funding Information
  • Science and Technology Commission of Shanghai Municipality (19YF1457300)
  • CAS-SAFEA International Partnership Program for Creative Research Teams (153631KYSB20190013)
  • Natural Science Foundation of Shandong Province (ZR2019ZD25)
  • Youth Innovation Promotion Association of the Chinese Academy of Sciences (2019283)
  • National Natural Science Foundation of China (81903548, 81690265, 81803444, 81521005, 32070927)

This publication has 51 references indexed in Scilit: